Is the level of patient co-payment for medicines associated with refill adherence in Sweden?

European Journal of Public Health

Volumn 24, Issue 1, 2013, Pages 85-90

  Leseán, Eva ^a,b   Sundell, Karolina Andersson ^a,c   Carlsten, Anders ^d   Mårdby, Ann Charlotte ^c,e   Jönsson, Anna K ^f  

^a NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^b Nordic Health Economics AB ^*  (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d MEDICAL PRODUCTS AGENCY   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; COST; FEMALE; HUMAN; INCOME; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PRESCRIPTION; REGISTER; STATISTICS; SWEDEN; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DEDUCTIBLES AND COINSURANCE; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INCOME; MALE; MEDICATION ADHERENCE; MIDDLE AGED; REGISTRIES; SWEDEN; YOUNG ADULT;

EID: 84898841248     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/ckt062     Document Type: Article

References (31)

1. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA 2008; 299:1922-8.
2. Conwell LJ, Esposito D, Garavaglia S, et al. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis. Am J Geriatr Pharmacother 2011;9:241-9.
3. Klepser DG, Huether JR, Handke LJ, Williams CE. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance. J Manag Care Pharm 2007;13:765-77.
4. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001;285:421-9.
5. Kemp A, Roughead E, Preen D, et al. Determinants of self-reported medicine underuse due to cost: a comparison of seven countries. J Health Serv Res Policy 2010; 15:106-14.
6. Schafheutle EI, Hassell K, Noyce PR, Weiss MC. Access to medicines: cost as an influence on the views and behaviour of patients. Health Soc Care Community 2002; 10:187-95.
7. Act (2002:160) on Pharmaceutical Benefits etc. [Lag (2002:160) om läkemedelsförmåner m.m.], Swedish code of statues [Svensk författningssamling (SFS)].
8. Andersson K, Melander A, Svensson C, et al. Repeat prescriptions: refill adherence in relation to patient and prescriber characteristics, reimbursement level and type of medication. Eur J Public Health 2005;15:621-6.
9. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314-19.
10. Manjunath R, Davis KL, Candrilli SD, Ettinger AB. Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy. Epilepsy Behav 2009;14: 372-8.
11. Davis KL, Candrilli SD, Edin HM. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population. Epilepsia 2008;49:446-54.
12. Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008;71:1572-8.
13. Lesén E, Sandström TZ, Carlsten A, et al. A comparison of two methods for estimating refill adherence to statins in Sweden: the RARE project. Pharmacoepidemiol Drug Saf 2011;20:1073-9.
14. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35.
15. Socialstyrelsen [National Board of Health and Welfare]. In English-the National Patient Register, [cited 2011 Nov 8]. Available at: http://www.socialstyrelsen.se/register/halsodataregister/patientregistret/inenglish.
16. Statistiska Centralbyrån [Statistics Sweden]. Longitudinal integration database for health insurance and labour market studies (LISA by Swedish acronym), [cited 2011 Nov 8]. Available at: http://www.scb.se/Pages/List-257743.aspx.
17. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659-67.
18. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-74, discussion 75-7.
19. Austin PC, Goel V, van Walraven C. An introduction to multilevel regression models. Can J Public Health 2001;92:150-4.
20. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6: 65-70.
21. Eaddy MT, Cook CL, O'Day K, et al. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T 2012;37:45-55.
22. Jones RM, Butler JA, Thomas VA, et al. Adherence to treatment in patients with epilepsy: associations with seizure control and illness beliefs. Seizure 2006;15:504-8.
23. Hovinga CA, Asato MR, Manjunath R, et al. Association of non-Adherence to antiepileptic drugs and seizures, quality of life, and productivity: survey of patients with epilepsy and physicians. Epilepsy Behav 2008;13:316-22.
24. Sweileh WM, Ihbesheh MS, Jarar IS, et al. Self-reported medication adherence and treatment satisfaction in patients with epilepsy. Epilepsy Behav 2011;21:301-5.
25. Nakhutina L, Gonzalez JS, Margolis SA, et al. Adherence to antiepileptic drugs and beliefs about medication among predominantly ethnic minority patients with epilepsy. Epilepsy Behav 2011;22:584-6.
26. Kephart G, Skedgel C, Sketris I, et al. Effect of copayments on drug use in the presence of annual payment limits. Am J Manag Care 2007;13(6 Pt 2): 328-34.
27. Andersson K, Petzold MG, Sonesson C, et al. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy 2006;79:231-43.
28. Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: a review of the literature. J Gen Intern Med 2007;22: 864-71.
29. Fendrick AM, Martin JJ, Weiss AE. Value-based insurance design: more health at any price. Health Serv Res 2012;47(1 Pt 2): 404-13.
30. Farley JF, Wansink D, Lindquist JH, et al. Medication adherence changes following value-based insurance design. Am J Manag Care 2012;18:265-74.
31. Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care 2004;42:626-34.